Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aerovate Therapeutics Inc (NQ: AVTE ) 1.560 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 4,202 Open 1.560 Bid (Size) 1.530 (6) Ask (Size) 1.550 (2) Prev. Close 1.560 Today's Range 1.560 - 1.560 52wk Range 1.250 - 32.41 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Nasdaq Surges Over 200 Points; Aaron's Shares Jump June 17, 2024 Via Benzinga Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 17, 2024 Via Benzinga Performance YTD -92.85% -92.85% 1 Month -90.87% -90.87% 3 Month -94.21% -94.21% 6 Month -93.28% -93.28% 1 Year -90.61% -90.61% More News Read More 12 Health Care Stocks Moving In Monday's Intraday Session June 17, 2024 Via Benzinga Recap: Aerovate Therapeutics Q4 Earnings March 25, 2024 Via Benzinga Recap: Aerovate Therapeutics Q3 Earnings November 13, 2023 Via Benzinga Recap: Aerovate Therapeutics Q1 Earnings May 15, 2023 Via Benzinga Crude Oil Rises 1%; Mustang Bio Shares Spike Higher June 17, 2024 Via Benzinga Exposures Fossil Fuels Why 90% Of Aerovate Therapeutics' Value Just Went Up In Smoke June 17, 2024 Via Investor's Business Daily Why Is Small Cap-Heart Disease Focused Aerovate Therapeutics Stock Plummeting On Monday? June 17, 2024 Via Benzinga US Stocks Mixed; Dow Tumbles Over 100 Points June 17, 2024 Via Benzinga Topics Stocks Exposures US Equities Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension June 17, 2024 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference May 21, 2024 From Aerovate Therapeutics, Inc. Via GlobeNewswire AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024 May 13, 2024 Via InvestorPlace Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights May 13, 2024 From Aerovate Therapeutics, Inc. Via GlobeNewswire Ermenegildo Zegna Reports FY23 Results, Joins Altice USA, Herbalife And Other Big Stocks Moving Lower On Friday April 05, 2024 Via Benzinga Topics Stocks Exposures US Equities Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference March 27, 2024 From Aerovate Therapeutics, Inc. Via GlobeNewswire AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023 March 25, 2024 Via InvestorPlace Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights March 25, 2024 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair March 06, 2024 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension November 20, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights November 13, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights August 14, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors July 11, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference June 01, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference May 22, 2023 From Aerovate Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
